Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Norton

Showing results (181-190 of 293) with videos related to

Pageof 30
Sort By:
JCO Precision Oncology|April 18, 2025
Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation TherapyJacqueline J Tao, Jeremy Setton, Pablo Sánchez Vela, et al.
JNCI Cancer Spectrum|July 31, 2019
The Landscape of Somatic Genetic Alterations in Breast Cancers from <i>CHEK2</i> Germline Mutation CarriersDiana Mandelker, Rahul Kumar, Xin Pei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group BMichael P DiGiovanna, David F Stern, Susan Edgerton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13William P Peters, Gary L Rosner, James J Vredenburgh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang, Gabriella M D'Andrea, Mary E Moynahan, et al.
Breast Cancer Research and Treatment|August 30, 2008
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinomaSteven Sugarman, Carolyn Wasserheit, Elizabeth Hodgman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 20, 2009
The 6q22.33 locus and breast cancer susceptibilityTomas Kirchhoff, Zhang-qun Chen, Bert Gold, et al.
Cancer|September 17, 2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancerPatrick G Morris, Neil M Iyengar, Sujata Patil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast CancerOtto Metzger Filho, Karla Ballman, Jordan Campbell, et al.
Pageof 30

Showing results (181-190 of 293) with videos related to

Sort By:
Pageof 30
JCO Precision Oncology|April 18, 2025
Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation TherapyJacqueline J Tao, Jeremy Setton, Pablo Sánchez Vela, et al.
JNCI Cancer Spectrum|July 31, 2019
The Landscape of Somatic Genetic Alterations in Breast Cancers from <i>CHEK2</i> Germline Mutation CarriersDiana Mandelker, Rahul Kumar, Xin Pei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group BMichael P DiGiovanna, David F Stern, Susan Edgerton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13William P Peters, Gary L Rosner, James J Vredenburgh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang, Gabriella M D'Andrea, Mary E Moynahan, et al.
Breast Cancer Research and Treatment|August 30, 2008
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinomaSteven Sugarman, Carolyn Wasserheit, Elizabeth Hodgman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 20, 2009
The 6q22.33 locus and breast cancer susceptibilityTomas Kirchhoff, Zhang-qun Chen, Bert Gold, et al.
Cancer|September 17, 2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancerPatrick G Morris, Neil M Iyengar, Sujata Patil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast CancerOtto Metzger Filho, Karla Ballman, Jordan Campbell, et al.
Pageof 30